Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

5 M&A Failed Deals: What Can You Learn From Them?

10/11/2021 | 08:09am EST

Mergers and acquisitions (M&A) are one of the fastest ways for a company to expand its presence into a new country or industry. But M&A or carve-out transactions are not easy. Here are five M&A deals that never took off, along with what we can learn from them.

A successful M&A or carve-out relies on several factors: trust between both parties, the financial status of the participants, a successful due diligence process, a favourable regulatory environment, agreement from shareholders, and more. Through years of experience, we've found that it's the little things that can make or break a deal, and also potentially rack up a large bill.

Here are the five M&A deals that didn't materialise and the likely reasons behind why:

1. Pfizer and Allergan

Deal size: US$152bn

Back in 2016, a deal between these pharmaceutical companies would have resulted in the biggest takeover for 15 years. It would have also provided Pfizer with the opportunity to relocate its headquarters overseas, ultimately lowering its tax bill.

However, the Obama administration tweaked the tax rules aimed at preventing 'corporate inversions', as American companies had been attempting to reduce their tax bills by shifting profits abroad. Those changes removed the financial advantages Pfizer hoped to get from buying Allergan, eventually causing the deal to be abandoned.

Cause: Regulatory environment

What we think could have been done better: Tax regulations are being reviewed and updated almost daily, all around the world. From substance requirements to transaction monitoring, we've seen it all. It is critical to have professionals providing timely updates and forecasting ahead. By reviewing the group and holding structure regularly, we work closely with our clients and their advisors to manage the potential risks and scenarios that may arise with impending deals.

2. Kraft Heinz and Unilever

Deal size: US$143bn

In 2017, US food giant Kraft Heinz shocked the business world by announcing a plan to buy Anglo-Dutch stalwart Unilever for US$143bn. Yet, two days after the announcement of the takeover bid, Kraft Heinz withdrew its offer, after Unilever had strongly rejected the bid.

Though much of the media focused on the political dimensions of the deal, a clash of corporate cultures may have been one of the prime reasons the takeover did not happen.

Cause: Due diligence and communication

What we think could have been done better: Mergers may be neat in theory, but the actual integration of two companies can be a tricky thing to successfully implement; it all comes down to the people on the ground. Language barriers, different working cultures and even discrepancies in core working hours and response times, can create much frustration if there is misalignment.

Relocating management from company headquarters to a new country, without any help, can also create possible problems for the business. Clients who approach us early during deal negotiations, to bridge the gap between headquarters and the local in-country requirements that become apparent during the transition period, typically fare much better at integration than those that look for help after the event - or after mass resignations from staff and angry notices from customers.

3. Honeywell and United Technologies

Deal size: US$90bn

When these two industrial conglomerates discussed a potential merger in 2015, the aim was to create a giant that would produce everything from thermostats to jet engines. The deal fell apart as United Technologies' stock price declined and the two firms' executives disagreed over the control of the merged entity.

Since United Technologies refused to accede to Honeywell's demands, Honeywell was forced to walk away.

Cause: Communication and corporate culture

What we think could have been done better: The companies should have looked to introduce a third voice at the start of the discussions, to help step into negotiations where there are multiple parties fighting over different priorities, from different points of view. As trustees, independent directors, neutral bookkeepers and tax agents, we bring clarity and transparency to the table, which keeps businesses growing, which ultimately benefits all parties.

4. Mondelez International and Hershey

Deal size: US$23bn

Mondelez, the owner of Cadbury and Nabisco, intended to buy its confectionery competitor, Hershey, but ceased its pursuit after the latter rejected an offer.

A number of factors were blamed, including Hershey's demands for a higher price and the legal uncertainty that surrounded Hershey's biggest shareholder.

Cause: Due diligence and valuation

What we think could have been done better: The best mergers are those where companies are able to deep dive during their financial and legal due diligence while pulling in local country experts, such as TMF Group, to perform physical due diligence on site.

5. Ant Financial and MoneyGram

Deal size: US$1.2bn

The US government blocked plans for a US$1.2bn takeover of US-based money transfer company MoneyGram International by Ant Financial, a financial arm of Chinese e-commerce giant Alibaba Group, over national security concerns.

Alex Holmes, CEO of MoneyGram, said: "The geopolitical environment has changed considerably since we first announced the proposed transaction with Ant Financial.

"Despite our best efforts to work co-operatively with the US government, it has now become clear that the Committee on Foreign Investment in the United States will not approve this merger."

Cause: Geopolitical environment

What we think could have been done better: Global M&A deals can be a sensitive topic to governments, depending on the timing and the circumstances. Corporations should always speak to administrators to find out how potential geopolitical issues may pose risks. We often find clients coming to us after the deal is done, trying to find alternative solutions due to in-country restrictions arising from embargos, trade wars or protectionist issues.

M&A and carve-out support

Working with a partner that provides administrative support services can help relieve some of the pressures faced by your deal and integration teams. Once the deal closes, you'll need to move quickly.

It's time to give a seat at the table to the only company that can conquer cross-border compliance complexity from our network of 125 offices, across more than 85 jurisdictions. Our 9,100 experts are dedicated to unlocking access to some of the world's most attractive markets - no matter how complex - swiftly, safely and efficiently.

You don't need to handle these challenges on your own. Talk to TMF Group today for help with your M&A or carve-out 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

TMF Group
TMF Group BV
6 St Andrew Street
Tel: 2078324900
Fax: 2078324900
E-mail: gareth.scurlock@tmf-group.com
URL: www.tmf-group.com

© Mondaq Ltd, 2021 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

Stocks mentioned in the article
ChangeLast1st jan.
PFIZER, INC. -3.00% 53.04 Delayed Quote.44.09%
RAYTHEON TECHNOLOGIES CORPORATION 3.30% 81.66 Delayed Quote.14.19%
THE KRAFT HEINZ COMPANY 1.13% 33.25 Delayed Quote.-4.07%
UNILEVER PLC 0.52% 3876 Delayed Quote.-11.84%
All news about PFIZER, INC.
05:29pU.S. administers 464.4 mln doses of COVID-19 vaccines - CDC
04:39pWall Street ends higher in robust rebound from Omicron-driven rout
02:25pDOJ, SEC Charge Former Immunomedics Finance Chief With Insider Trading
12:29pWhat COVID-19 vaccine and drug makers have to say about Omicron
09:40aAmazon Web Services, Pfizer Collaborate to Improve New Medicine Development, Distributi..
07:06aCovid-19 - Mobile Vaccination Teams Deployed to Weekly Markets, Inland Regions
05:10aHARVARD UNIVERSITY : Moderna edges out Pfizer vaccine in head-to-head comparison; Large-sc..
12/01UK Secures 114 Million Additional COVID-19 Shots From Pfizer/BioNTech, Moderna
12/01Hexima Names New Chief Development Officer
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 517 M - -
Net income 2021 21 354 M - -
Net Debt 2021 27 873 M - -
P/E ratio 2021 13,6x
Yield 2021 2,97%
Capitalization 298 B 298 B -
EV / Sales 2021 3,99x
EV / Sales 2022 3,76x
Nbr of Employees 78 500
Free-Float 59,3%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 53,04 $
Average target price 49,58 $
Spread / Average Target -6,53%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.44.09%306 912
JOHNSON & JOHNSON0.44%416 161
ROCHE HOLDING AG18.38%343 323
NOVO NORDISK A/S66.91%247 444
ABBVIE INC.8.18%204 915